Anavex Life Sciences Corp. reported it remains in the pre-revenue stage with no revenues recorded for the fiscal year ending September 30, 2025. The company had $102.6 million in cash and cash equivalents at the end of the period, a decrease from $132.2 million the previous year. Working capital stood at $94.9 million, down from $120.3 million in fiscal 2024. Cash used in operating activities increased to $39.0 million from $30.8 million in 2024. General and administrative expenses rose to $13.8 million, primarily due to higher legal and regulatory costs. Research and development expenses decreased, reflecting the completion of several clinical trials, including the ATTENTION-AD trial for Alzheimer's and the ANAVEX2-73 EXCELLENCE OLE for Rett syndrome, partially offset by increased spending on completion of Part B of the ANAVEX3-71-SZ-001 trial. The company plans to continue using its capital resources to advance clinical trials and pipeline development.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anavex Life Sciences Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001731122-25-001596), on November 25, 2025, and is solely responsible for the information contained therein.
Comments